(±)-TRAMADOL
Neuropathic Pain
Aretaieion University HospitalSmall moleculePhase 4 / ApprovedActive
BB
71/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 70/ 100
- Competitive Position
- 73/ 100
Competitive context
55 Active assets in the Neuropathic Pain cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LIDOCAINE Ataturk University | Phase 4 | BBB |
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Medipol University | Phase 4 | BBB |
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Margaux M. Salas, PhD | Phase 4 | BBB |
Nabilone Eldon Loh, MD | Phase 4 | BBB |
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)- University of British Columbia | Phase 4 | BB |
View all 50 →
Same molecule, other indications
(±)-TRAMADOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →